$2.5M
+$2.5M this year1 filing since 2026 · latest Equity filed
BioStem Technologies is a regenerative medicine company that develops, manufactures, and commercializes allografts derived from perinatal (placental) tissue. It operates an AATB-accredited, FDA-registered facility running under cGMP standards in Pompano Beach, Florida. Its products are used primarily in chronic and acute wound care and in surgical applications. The company trades publicly and has announced a Nasdaq uplisting along with the acquisition of BioTissue Holdings' surgical and wound care business.
What sets it apart
Its proprietary BioRetain processing method is designed to preserve the endogenous biological properties, structure, and matrix of fresh perinatal tissue rather than devitalizing it, which the company positions as a differentiator against conventionally processed amniotic allografts.
A placental-derived amniotic membrane allograft processed with BioStem's BioRetain method, applied as a wound covering in chronic and acute wound care.
